Shots:

• The first patient has been dosed in the P-IIa expansion portion of P- I/IIa study- assessing BT1718 (qw) at RP2D of 20 mg/m2  in patients with MT1-MMP+ sq. NSCLC and a basket of other MT1-MMP+ solid tumors
• The focus of the study is to evaluate the safety and tolerability profiles of BT1718 while the secondary objective is to assess the anti-tumor response. The study is sponsored by Cancer Research UK
• BT1718 is a BTC targeting MT1-MMP and is consist of a mono-hindered disulfide cleavable linker and a cytotoxic DM1 payload

­ Ref: Businesswire | Image: Businesswire